[en] Metabolically obese normal-weight (MONW) individuals are frequently not detected because of a falsely reassuring body weight. However, they have most of the metabolic syndrome markers known to be associated with a higher risk of type 2 diabetes, cardiovascular disease and mortality. The present review paper aims to describe the clinical consequences to which MONW people are exposed and the main principles of managing this syndrome [fr] Les personnes non obèses « métaboliquement anormales » (MONW) sont rarement dépistées en raison d’un poids corporel faussement rassurant. Elles présentent pourtant bon nombre de marqueurs du syndrome métabolique, connus pour être associés à un risque accru de diabète de type 2, de maladies cardiovasculaires et de mortalité. Cet article vise à évaluer les conséquences cliniques auxquelles sont exposées les personnes MONW et à décrire les grands principes de la prise en charge thérapeutique de ce syndrome.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Beck, Emmanuel ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Paquot, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Language :
French
Title :
Sujets « métaboliquement obèses » de poids normal. Seconde partie: pronostic et prise en charge
Alternative titles :
[en] Metabolically obese normal-weight subjects. Part two: prognosis and management
Publication date :
2008
Journal title :
Obésité: Revue Francophone pour la Recherche Clinique, la Prévention et la Prise en Charge de l'Obésité
E. Beck A.J. Scheen 2008 Sujets « métaboliquement obèses » de poids normal. Première partie: diagnostic, physiopathologie et prévalence Obésité 3 184 193
N. Ruderman D. Chisholm X. Pi-Sunyer S. Schneider 1998 The metabolically obese, normal-weight individual revisited Diabetes 47 699 713
F. Conus R. Rabasa-Lhoret F. Peronnet 2007 Characteristics of metabolically obese normal-weight (MONW) subjects Appl Physiol Nutr Metab 32 4 12
L.F. Van Gaal I.L. Mertens C.E. De Block 2006 Mechanisms linking obesity with cardiovascular disease Nature 444 875 880
J.P. Després I. Lemieux J. Bergeron 2008 Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk Arterioscler Thromb Vasc Biol 28 1039 1049
R. Kahn J. Buse E. Ferrannini M. Stern 2005 The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 28 2289 2304
J.B. Meigs P.W.F. Wilson C.S. Fox 2006 Body mass index, metabolic syndrome and risk of type 2 diabetes or cardiovascular disease J Clin Endocrinol Metab 91 2906 2912
P.T. Katzmarzyk T.S. Church I. Janssen 2005 Metabolic syndrome, obesity and mortality. Impact of cardiorespiratory fitness Diabetes Care 28 391 397
M. Wei J.B. Kampert C.E. Barlow 1999 Relationship between low cardiorespiratory fitness and mortality in normal-weight, overweight and obese men JAMA 282 1547 1553
A.C. Saint-Pierre B. Cantin P. Mauriège 2005 Insulin resistance syndrome, body mass index and the risk of ischemic heart disease CMAJ 172 1301 1305
The DECODE Study Group 2008 Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J Obes 32 757 762
A.M. Fontbonne G. Tchobroutsky E. Eschwege 1988 Coronary heart disease mortality risk: plasma insulin level is a more sensitive marker than hypertension or abnormal glucose tolerance in overweight males. The Paris Prospective Study Int J Obes 12 557 565
J.P. Empana P. Ducimetière M.A. Charles X. Jouven 2004 Sagittal abdominal diameter and risk of sudden death in asymptomatic middle-aged men: the Paris Prospective Study I Circulation 110 2781 2785
L. Guize F. Thomas B. Pannier 2006 Syndrome métabolique: prévalence, marqueurs de risque associés et mortalité dans une population française de 62 000 sujets Bull Acad Natl Med 190 685 700
E.S. Ford 2005 Risks for all-cause mortality, cardiovascular disease and diabetes associated with the metabolic syndrome. A summary of the evidence Diabetes Care 28 1769 1778
B. Balkau J.E. Deanfield J.P. Després 2007 International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease and diabetes mellitus in 168 000 primary care patients in 63 countries Circulation 116 1942 1951
S. Yusuf S. Hawken S. Ounpuu 2005 Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study Lancet 366 1640 1649
A.J. Scheen 2004 Management of the metabolic syndrome Minerva Endocrinol 29 31 45
S.M. Grundy J.I. Cleeman S.R. Daniels 2005 Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung and Blood Institute Scientific Statement Circulation 112 2735 2752
J. Lindström P. Ilanne-Parikka M. Peltonen 2006 Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study Lancet 368 1673 1679
A. Basdevant M. Laville O. Ziegler 1998 Recommandations pour le diagnostic, la prévention et le traitement des obésités Diab Metab 24 Suppl2 1 48
Scheen AJ (2007) Diabetes, obesity and metabolic syndrome. In: Meckling KA (ed) Nutrient-drug interactions. CRC Press Taylor & Francis, Boca Raton, FL, US, pp. 1-30
Scheen AJ (2007) Nutritional counseling for overweight patients and patients with metabolic syndrome. In: Perk J, Mathes P, Gohlke H, et al. (eds) Cardiovascular prevention and rehabilitation. Springer-Verlag, London, UK, pp. 201-211
A. Chiolero D. Faeh F. Paccaud J. Cornuz 2008 Consequences of smoking for body weight, body fat distribution and insulin resistance Am J Clin Nutr 87 801 809
O. Colombo S. Villani G. Pinelli 2008 To treat or not to treat: comparison of different criteria used to determine whether weight loss is to be recommended Nutr J 7 5
S.E. Feldeisen K.L. Tucker 2007 Nutritional strategies in the prevention and treatment of metabolic syndrome Appl Physiol Nutr Metab 32 46 60
K. Esposito M. Ciotola D. Giugliano 2007 Mediterranean diet and the metabolic syndrome Mol Nutr Food Res 51 1268 1274
D.M. Minich J.S. Bland 2008 Dietary management of the metabolic syndrome beyond macronutrients Nutr Rev 66 429 444
A.J. Scheen N. Paquot 2001 Effets bénéfiques de l'activité physique sur les facteurs de risque cardiovasculaire Rev Med Liège 56 239 243
T.A. Lakka D.E. Laaksonen 2007 Physical activity in prevention and treatment of the metabolic syndrome Appl Physiol Nutr Metab 32 76 88
J.M. Gill D. Malkova 2006 Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity Clin Sci (Lond) 110 409 25
K.D. DuBose J.C. Eisenmann J.E. Donnelly 2007 Aerobic fitness attenuates the metabolic syndrome score in normal-weight, at-risk-for-overweight, and overweight children Pediatrics 120 e1262 e1268
A.J. Scheen 2008 The future of obesity: new drugs versus lifestyle interventions? Exp Opin Invest Drugs 17 263 267
D. Rucker R. Padwal S.K. Li 2007 Long-term pharmacotherapy for obesity and overweight: updated meta-analysis BMJ 335 1194 1199
A.J. Scheen N. Paquot 2007 Pharmacological treatment of obesity, food intake and reversal of metabolic disorders Curr Nutr Food Sci 3 123 133
A. Fontbonne M.A. Charles I. Juhan-Vague BIGPRO Study Group 1994 The effect of metformin on the metabolic abnormalities associated with upper body fat distribution Diabetes Care 19 920 926
Y. Miyazaki A. Mahankali M. Matsuda 2002 Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients J Clin Endocrinol Metab 87 2784 2791
H. Bays C.A. Dujovne 2006 Adiposopathy is a more rational treatment target for metabolic disease than obesity alone Curr Atheroscler Rep 8 144 156
